|Bid||3.2800 x 3200|
|Ask||3.2800 x 4000|
|Day's Range||3.2100 - 3.3300|
|52 Week Range||1.6700 - 9.0200|
|Beta (5Y Monthly)||2.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation 2021 first-quarter financial results and corporate update conference call. On the call from Arbutus executive team are Bill Collier, president and chief executive officer; Dave Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer.
Arbutus (ABUS) delivered earnings and revenue surprises of 4.55% and -45.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders might be concerned after seeing the share price drop 18% in...